A Trial to Evaluate the Effect of Esomeprazole on the Pharmacokinetics of Emraclidine in Healthy Adult Participants - Trial NCT06366243
Access comprehensive clinical trial information for NCT06366243 through Pure Global AI's free database. This Phase 1 trial is sponsored by Cerevel Therapeutics, LLC and is currently Not yet recruiting. The study focuses on Healthy Participants. Target enrollment is 20 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Cerevel Therapeutics, LLC
Timeline & Enrollment
Phase 1
May 10, 2024
Jun 24, 2024
Primary Outcome
Maximum Observed Plasma Concentration (Cmax) of Emraclidine,Time to Maximum (Peak) Plasma Concentration (Tmax) of Emraclidine,Area Under the Plasma Concentration-time Curve From Time 0 to the Time of Last Quantifiable Concentration (AUC0-t) of Emraclidine,Area Under the Plasma Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of Emraclidine
Summary
The primary purpose of this study is to evaluate the potential of gastric pH-dependent
 drug-drug interaction effect of esomeprazole, a proton pump inhibitor (PPI), on the
 pharmacokinetics (PK) of emraclidine in healthy adult participants.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06366243
Non-Device Trial